Page 3 - Tom Graney News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”). On Septe

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on September 14, 2023, from Atlas Special Oppor

Regulated Information – Inside Information Waives Key Conditions for Up to €3.5 Million in Atlas FundingReduces Cash Covenant and Total Debt for Kreos/Pontifax Loan Leuven, BELGIUM,...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 1, 2023 – 7.00 PM CET Oxurion NV , a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...

Regulated Information Leuven, BELGIUM, Boston, MA, US – August 23, 2023 – 8.00 PM CET Oxurion NV , a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...